Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in individuals with type 1 diabetes

Ähnliche Einträge

• Cost‐utility of once‐weekly insulin icodec versus once‐daily basal insulins for type 2 diabetes in China
  von: Xichen Tong, et al.
  Veröffentlicht: (2026)
• Characterisation of steady‐state pharmacokinetics and glucodynamics of once‐weekly insulin efsitora alfa in individuals with type 2 diabetes
  von: Jennifer Leohr, et al.
  Veröffentlicht: (2026)
• Cost‐utility analysis of once‐weekly insulin icodec and once‐daily insulin glargine in patients with type 2 diabetes receiving basal‐bolus insulin therapy in China
  von: Nan Dai, et al.
  Veröffentlicht: (2024)
• Efficacy and safety of once‐weekly insulin icodec versus once‐daily basal insulin in Japanese individuals with type 2 diabetes: A subgroup analysis of the ONWARDS 1, 2 and 4 trials
  von: Hirotaka Watada, et al.
  Veröffentlicht: (2024)
• Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in individuals with type 2 diabetes by kidney function: A post hoc participant‐level analysis of the ONWARDS 1–5 trials
  von: Peter Rossing, et al.
  Veröffentlicht: (2025)